Investigational drug · Phase 2
CSTI-500
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Prader-Willi Syndrome.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "CSTI-500"
First trial start
2026
May 18, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CSTI-500", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prader-Willi Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "CSTI-500" as an intervention, largest first.
ConSynance TherapeuticsIndustry
NCT07348601 · 12 participants (planned) · Start May 18, 2026 · Primary completion Jun 2027
Drug: CSTI-500 · For: Prader-Willi Syndrome
Sites: Nashville, Tennessee
ConSynance TherapeuticsIndustry
NCT05504395 · 10 participants · Start Nov 14, 2022 · Primary completion Feb 21, 2023
Drug: CSTI-500 · For: Prader-Willi Syndrome
Sites: Nashville, Tennessee
Newest research
PubMed records naming it or its code names, newest first.
- Ascending single-dose study of the safety, pharmacokinetics, and pharmacodynamics of CSTI-500, a novel monoamine triple reuptake inhibitor, first-in-human.
Appel L, Risinger R, Wall A, et al. · Psychopharmacology (Berl) 2026
Also in development for Prader-Willi Syndrome
- BMB-101Phase 22 trials
Bright Minds Biosciences Pty Ltd · Absence Epilepsy, Jeavons Syndrome, Dravet Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.